What Avala Treats: Main Uses and Benefits

Avala (Cimicifuga racemosa extract) is commonly used for the symptomatic relief of complaints associated with the climacteric syndrome in adult women. Its therapeutic relevance is focused on easing the overall symptom burden across key domains that disrupt daily comfort and stability.

The medicine is used for the relief of menopausal complaints.

---

Managing Vasomotor and Neuropsychological Symptoms

The treatment is considered relevant in clinical settings marked by episodic or fluctuating symptom patterns. It helps address symptom clusters that may become intense or disruptive, including hot flashes, profuse sweating (especially night sweats), nervousness, irritability, and mood swings. Easing these manifestations offers symptomatic relief that helps patients cope more steadily, which may assist with maintaining functional stability.

---

Supportive Non-Hormonal Option

The medication is commonly used as a non-hormonal alternative for climacteric complaints in peri- and postmenopausal women. This application is relevant in contexts involving heightened systemic burden, offering symptomatic assistance in situations where patients experience discomfort and may be seeking non-hormonal management options.

Quick Fact: Relief for Vasomotor and Neuropsychological Symptoms

Regulatory References

1. European Union herbal monograph on Cimicifugae rhizoma

Eligibility Map: Who Can and Cannot Use Avala

This section defines the official eligibility and non-eligibility rules for Avala (Cimicifuga racemosa extract) as stated in authoritative government regulatory documents.

---

Category	Official Regulatory Status
Populations for whom use is allowed	Adult women (18 years and older). Use is indicated for the adult population only.
Populations for whom use is contraindicated	Pregnant women (Pregnancy). Use is explicitly prohibited.
	Individuals with a current or previous liver disorder.
	Individuals with known hypersensitivity to the active substance.
Populations for whom use is not recommended	Individuals who are breastfeeding/lactating due to insufficient data.
Pediatric Population	Not for use in children and adolescents under 18 years.

---

Condition-Specific Eligibility Rules

• Hormone-Dependent Tumours: Patients who have been treated or are undergoing treatment for breast cancer or other hormone-dependent tumours should not use the preparation without medical advice.
• Hepatic Impairment: Use is contraindicated for those with current or previous liver disorders. Immediate discontinuation is required if signs of liver injury, such as jaundice, develop.

---

Resulting Eligibility Structure

The official eligibility profile limits use strictly to adult women (18+). The label explicitly establishes absolute prohibition for pregnant women and individuals with current or previous liver disorders. The profile also mandates special caution and medical supervision for patients with a history of hormone-dependent tumours before the medicine can be used.

Avala Interactions with other medicines and products

This section summarizes the officially documented interaction information for Avala ( Cimicifuga racemosa extract), based strictly on government regulatory documents.

---

Documented Interaction Cautions

The interaction profile is primarily defined by specific co-administration restrictions related to the drug's non-hormonal classification and its association with rare liver reactions.

Category of Interacting Product	Regulatory Caution
Hormonal Agents (Oestrogens/HRT)	Co-administration is not recommended and should only occur under strict medical supervision.
Potentially Hepatotoxic Agents	Use is cautioned against with products that may cause liver injury, including alcohol, due to the potential for an additive risk.

---

Population-Specific Interaction Notes

Regulatory documents emphasize that the risk of interaction or adverse outcomes is elevated in specific patient populations, requiring expert clinical assessment before use:

• Patients with a history of liver disorder: The preparation must be used with caution due to the potentially heightened risk of liver injury.
• Patients with hormone-dependent tumours: Use is strongly advised against without the guidance of a physician, particularly in patients with or treated for breast cancer.

No formal restrictions requiring timing separation or mandatory dose adjustments are documented for co-administered medicines in official regulatory labels. While the potential for CYP3A4 involvement has been noted in regulatory reviews, no established restriction is currently formalized.

How Avala Works: Mechanism of Action

Avala functions as a selective agonist of the Parathyroid Hormone Type 1 Receptor (PTH1R). This receptor is a G-protein-coupled receptor (GPCR) expressed on the surface of target cells, including osteoblasts and osteocytes. The compound preferentially binds to the transient (RG) conformation of the PTH1R, promoting a short-duration pulse of intracellular signaling.

This binding activates the Gs-protein signaling cascade, primarily stimulating adenylyl cyclase (AC) and increasing the concentration of cyclic adenosine monophosphate (cAMP) within the cell. This specific, transient modulation of the cAMP/PKA pathway in osteoblasts stimulates their differentiation and activity. The resulting cellular consequence is a net increase in the formation of new mineralized tissue and the promotion of bone-remodeling units at the system level, without causing a sustained increase in bone resorption.

How to Use Avala

This section describes the administration principles and schedules for Avala (Cimicifuga racemosa extract).

---

Official Administration Guidelines

Instruction Entity	Standard Administration Statement
Route of administration	Oral administration only.
Dosing schedule	The daily dose is standardized to an extract equivalent of 40 mg of Cimicifuga racemosa herbal substance (crude drug). The specific milligram dose of the dry extract varies by formulation.
Frequency and timing	Administration is typically scheduled as once daily or in divided doses twice daily, depending on the standardized strength of the product's formulation.
Age-group rules	Use is restricted solely to adult women experiencing climacteric symptoms. It is not indicated for men, children, or adolescents.
Course duration	If symptoms persist or worsen after six weeks of use, professional consultation is necessary. Continuous treatment should generally not exceed six months without review by a healthcare professional.

---

Procedural Context

Avala is administered via the oral route as an intact capsule or tablet. Guidelines do not provide a universal instruction regarding administration with or without food. The instruction set establishes a precise dosing equivalent and a clear time-bound protocol. This framework regulates how the medicine is to be started, maintained, and concluded.

Research Evidence / Overview of Studies

Research Focus: Osteoarthritis

Research has examined the findings related to joint function and the measurements of pain in patients with osteoarthritis. Studies have examined the tolerability profile during long-term use; however, individuals may wish to discuss the findings related to long-term use with a healthcare professional.

---

Combination Therapy Trials

Clinical trials have focused on combining the primary compound with a secondary anti-inflammatory agent. One study reported findings that included lower measurements of inflammation and pain in the combination therapy group. Research has also investigated the measurements of symptoms over extended timeframes using this combination; however, comparative data remains limited. Studies have also examined potential cardiovascular risks, and individuals with pre-existing heart conditions may wish to discuss the cardiovascular risks examined in these studies with their healthcare professional.

---

Pharmacological Mechanism of Action

Studies have explored potential actions of the compound, and research is ongoing regarding the clinical significance of these potential actions.

---

Tolerability and Subpopulations

Studies have focused on the overall tolerability profile. Studies examining dosing protocols included initial groups receiving the lowest dose. Newer studies have investigated whether the effect differs in younger patients. The studies examined the compound's tolerability profile across the patient groups studied. Individual responses may vary.

Common questions about Avala (FAQ)

Q: Is Avala a type of antibiotic?

Avala is officially classified as a Phytotherapy Agent or Herbal Medicinal Product because it is derived from the Cimicifuga racemosa plant. This places it in a therapeutic category that is distinct from synthetic pharmaceuticals like antibiotics.

Q: Do I need a special diet while taking Avala?

Official regulatory documents do not typically list restrictions on specific foods while taking Avala. However, caution is advised regarding the use of alcohol due to the potential for an additive risk of liver injury.

Q: How long does it typically take for Avala to start working?

Official guidance indicates that if climacteric symptoms persist or worsen after approximately six weeks of use, it is advised that a healthcare professional be consulted. This period serves as the initial timeframe for assessing the medicine’s expected activity.

Q: Can Avala affect my ability to drive or operate machinery?

Regulatory documents listing the known common side effects of Avala do not typically include symptoms like dizziness or drowsiness, which would usually lead to restrictions on driving or operating machinery. Reviewing the product's specific patient leaflet is a way to find complete safety information.

Q: Does Avala have a risk of causing long-term side effects?

Continuous use of Avala should generally not exceed six months without review by a healthcare professional, according to official guidance. The most serious risk noted in the safety profile is severe liver injury (hepatotoxicity), which is classified as rare.

Q: Can Avala be taken by people with kidney problems?

Official regulatory documents do not list kidney problems as a specific contraindication (a reason not to use the medicine). The major non-eligibility rule is for individuals with a current or previous liver disorder.

Q: Are there any known interactions between Avala and common over-the-counter pain relievers?

The product is cautioned against co-administration with any agents that may potentially cause liver injury (hepatotoxic agents). This may include some common over-the-counter pain relievers, although they are not listed by name in the regulatory documents.

Q: How long after stopping Avala does it stay in the system?

Pharmacokinetic data from studies suggests that the active chemical markers in the extract have a relatively short elimination half-life. This means the measurable compound is processed and leaves the system relatively quickly after the last dose is administered.

Q: How is the effectiveness of Avala measured in clinical trials?

Clinical trials measure effectiveness by assessing changes in relevant symptoms using validated rating scales. This includes the measurement of joint function and pain, as well as common climacteric symptoms such as hot flashes and mood changes.

Q: Can Avala cause changes in mood or sleep patterns?

Avala is used to help relieve climacteric symptoms, which themselves can include sleep disturbances and mood swings. Research related to the medicine often includes the measurement of these psychological and sleep-related symptoms as clinical endpoints.

Q: What is Avala used for besides the main condition it treats?

The officially indicated therapeutic purpose of Avala is strictly the relief of climacteric symptoms and associated menopausal complaints in adult women. Official regulatory documents do not list any other indicated uses.

Q: Does Avala require a special monitoring or lab tests?

While routine, mandatory lab testing is not typically stated, official labeling requires patients to be aware of and monitor for signs of liver damage (such as unusual fatigue, dark urine, or yellowing of the skin). Seeking immediate medical attention is required if these signs develop.

Q: Does Avala carry a specific FDA Black Box Warning?

Government regulatory documents highlight the potential, rare risk of severe hepatotoxicity (liver injury) in the safety profile. However, official information does not state that the product carries a specific FDA Black Box Warning.

Q: Can I take Avala if I already take a blood pressure medication?

Formal regulatory documents specifically list cautions for Hormonal Agents and Potentially Hepatotoxic Agents. There are no established formal restrictions currently stated for co-administered blood pressure medications.

Q: How soon will I know if Avala is not the right medicine for me?

Official guidance states that if your climacteric symptoms persist or worsen after a period of six weeks of use, consultation with a healthcare professional is recommended to review the treatment plan.

Q: What kind of warnings are included on the patient information leaflet for Avala?

The warnings generally include a prohibition on use during pregnancy, caution against use in patients with hormone-dependent tumors, and emphasis on recognizing signs of liver injury.

Q: Does Avala have any known contraindications related to mental health conditions?

No formal contraindications (reasons not to use) related to specific mental health conditions are listed in the regulatory documents. The contraindications are primarily limited to pregnancy, liver disorders, and hypersensitivity.

Regulatory documents do not provide specific, official storage temperature requirements or in-use stability periods for a product named Avala. In the absence of detailed labeling, the product should be kept in its original packaging in a location protected from moisture, excessive heat, and direct light, and out of sight and reach of children.

Disposal Guidelines

Specific labeled instructions for the disposal of Avala are not documented in major governmental sources (FDA, EMA). To safely dispose of any unused or expired medication that does not have explicit flushing instructions:

• Preferred Method: Utilize a community drug take-back program or a drug mail-back service. These options are available at many pharmacies and police stations and are the safest way to dispose of most drugs.
• Household Trash: If a take-back option is unavailable, remove the medicine from its original container, mix it with an unappealing substance (like dirt or used coffee grounds), seal the mixture in a plastic bag, and place it in the household trash. This prevents accidental ingestion by people or pets.